Tag: IPO

  • Barkat Frisian’s IPO to fetch up to 1.23 billion on 17 & 18 February

    Barkat Frisian Agro Limited, a joint venture of Frisian Egg Group of Netherlands and Pakistan’s Buksh Group, is all set to raise up to 1.2 billion financing from PSX through the book building process on 17th and 18th February.

    The Securities and Exchange Commission of Pakistan (SECP) and the Pakistan Stock Exchange (PSX) have approved the prospectus and IPO dates including book building dates and the public subscription dates, said Chief Executive Officer of Arif Habib Limited Shahid Ali Habib the lead manager and book runner for the IPO.

    The Barkat Frisian Agro plans to raise up to Rs 1.23 billion through selling 67,735,000 of its ordinary shares in the IPO. The book building dates are Feb 17th and 18th, and the public subscriptions dates are 24th and 25th February.

    Barkat Frisian Agro, according to Shahid Ali Habib, is Pakistan’s largest manufacturer of pasteurized egg products, which plans to sell its shares each at a floor price of Rs. 13 through 100% book building method.

    The fund raised from equity investors will be used for building a new state-of-the-art production facility at the Special Economic Zone of Faisalabad, which is fast becoming an industrial hub at the heart of Punjab province.

    The company is operating a manufacturing plant in Pakistan’s commercial capital Karachi, and the new plant will increase its pasteurized eggs’ production capacity by 71% to 29,000 tons per year from the existing 17,000 tons.

    The Pakistan-Dutch Joint Venture produces and markets a variety of products, including pasteurized eggs, egg whites, egg yolks, and customized egg based products that are supplied to food manufacturers.

    The new plant is being set up to meet inflating demand from the company’s domestic and overseas customers, said CEO of Barkat Frisian Muhammad Adil.

    In the IPO, the bidders will be allowed to place bids for 100% of the issue size, and the strike price shall be the price at which the 100% of the issue is subscribed.

    The successful bidders, however, will be provisionally allotted only 75% of the issue size, i.e., 50,801,250 shares, and the company will offer the remaining 25% or 16,933,750 shares to the retail investors through the general public subscription.

    Also Read: ABHI empowers PayPeople to enhance employee well-being

  • Expansion for exports and local manufacturing of hi-tech pharmaceuticals: BF Biosciences Plans to Raise Rs1.38 bn to 1.93 bn in Sept. 2024 through IPO

    BF Biosciences Limited looks to raise 1.38 bn to 1.93 bn through issuing 28.3% new shares through an Initial Public Offering (IPO) on September 25-26.

    Speaking at the pre-IPO investors road show held in Karachi, Mr. Osman Khalid Waheed Director of BF Biosciences informed that BF Biosciences, a leader in the biotech pharmaceuticals sector in Pakistan, is raising between 1.38 and 1.93 billion PKR to expand its key product lines and obtain export certifications. This strategic initiative is expected to drive significant growth in both the company’s topline and profitability as company has already completed a brownfield expansion and IPO will also help the company to manage working capital needs of the aforesaid expansion.

    Mr. Farhan Rafiq, COO BF Biosciences informed investors that Pakistan’s first biopharmaceutical manufacturer, BF Biosciences Limited, is a joint venture company of Ferozsons Laboratories Ltd and Bago Group of Argentina, each holding 80% and 20% stake in it respectively.He appraised the investors that company has already completed a brownfield expansion worth Rs 4 billion and the project is financed at a finance cost of around 2.5% for 10 years, while the majority of the expansion was completed at Rupee dollar parity of 200. He appraised the audience about the growth potential of a few of the emerging products company recently launched which includes Ferulin (Insulin) Sematide (semaglutide) and Noxane (Enoxaparin sodium).

    Mr. Sebastian Martin Ferrarassi, Chairman of the Board of BF Biosciences shared with the investors that BF was the first investment of the Bago Group of Argentina outside Latin America. Mr. Ferrarassi shared the Group’s journey in partnership with Ferozsons, from their initial partnership in 2003 to commissioning BF Biosciences Limited, Pakistan’s first Biotech Plant in 2009.

    The Group not only invested equity in the facility but also undertook valuable technology transfer and training of BF Staff in producing biotech products. Mr. Ferrarassi said that it is a proud moment for the company and expressed his confidence about the company’s growth prospects.
    The floor price for the issue has been set at Rs 55 per share through a 100% book building process.

    Initially, 18.8 million shares or 21.23% of the issue size would be allotted to the successful bidders, while 6.25 million shares or 7.07% of the issue would go to the retail investors.

    The unsubscribed shares, if any, of the general subscription portion would be allocated to the successful bidders of the book building portion on a pro-rata basis.

    The issuer will utilize any additional funds raised above the floor price in managing its additional requirements for capex and working capital needs.

    BF Biosciences has estimated that the maximum strike price for the IPO may climb to Rs 77 per share that would increase the funds raised to Rs 1.93 billion.

    Once fully subscribed, the IPO will bring down the respective shareholdings of Ferozsons Laboratories and Bago Group of Argentina to 57.36% and 14.34% in BF Biosciences.

    Arif Habib Limited has been appointed as a lead manager and book runner to the issue.

    The company, once raised, will primarily spend Rs 560 million of the funds on buying plant and machinery to expand its product range and improve efficiency.

    It would use another Rs 141 million to acquire export certifications such as PIC/S and SRA and new product development including Glucagon-like Peptide (GLP1) while Rs 674 million have been allocated to finance the company’s working capital requirements for purchasing raw and packing materials to meet post-expansion working capital needs.

    The core business of BF Biosciences, which was incorporated as an unlisted public limited company in 2006, involves the import, manufacturing, marketing, and distribution of pharmaceutical products in Pakistan. The company started local manufacturing in 2009 through Line 1.

    Mr. Shahid Habib, CEO Arif Habib Ltd said that BF Biosciences distinguishes itself by producing life-saving medications that are accessible to all and has propelled Pakistan into the exclusive league of exporters of biotech pharmaceuticals, especially during the Covid 19 pandemic.

    BF Biosciences has a state-of-the-art biotech manufacturing plant located in Lahore that was designed and executed by Telstar Projects.

    The plant produces biological medicines for cancer, chronic kidney disease and Hepatitis C and caters the local and international markets.

    Currently, in this manufacturing facility the company has two manufacturing lines named “Line I” and “Line II”.

    During COVID-19, BF Biosciences was one of Pakistan’s leading pharmaceutical exporters selling medicines to countries like Indonesia, Belarus, Ukraine etc.

    Soon after the commencement of Line II operations, the company is targeting PIC/S certification after which it will be aggressively exploring export markets.

    BFBL is actively pursuing new registrations and plans to initiate exports to non-PIC/S nations.

    The company is targeting Central American countries, where regulatory requirements are less stringent and where its joint venture partner, Bagó has a strong equity.

    Additionally, the BF Biosciences’ parent company, Ferozsons Laboratories, already has a strong presence in Far Eastern and Central Asian countries, which are the markets of their primary focus in the short and medium term.

    Secure Logistics Group Ltd’s Book Building Starts from 27th March

  • IPAK Raises PKR 1.77 billion in Book Building Process!

    The book building process of International Packaging Films Limited’s (IPAK) Initial Public Offer (IPO) has concluded with an oversubscription of 1.73 times, the company said today.

    “The IPO received an overwhelming response from institutional investors and high-net worth individuals as the strike price clocked in at Rs 25.2 per share, higher than the floor price of Rs 21 the leading flexible packaging films manufacturer of the country said in a statement.

    International Packaging Films Limited is going to raise Rs 1.77 billion in total. Ipak listing is a significant event as Ipak is the largest manufacturer of flexible packaging film.

    Several brokerages had issued almost unanimous calls to ‘subscribe,’ which resulted in investor demand amounting to Rs 1.77 billion against the IPO’s book-building size of Rs 1.47 billion at the floor price.

    The general public will subscribe to 17,526,364 shares (25 percent of the total offer size) on May 15-16 at the strike price of Rs 25.2, the company said. The proceed from IPO will be utilized to pay off some of the debts.

    Naveed Godil, CEO International Packaging Films Limited, in his message thanked investors for their overwhelming response.

    International Packaging Films Limited IPO Receives Overwhelming Response from Investors!

    Muhammed Amin, Chairman of International Packaging Films Limited expressed his gratitude for the confidence of investors in the company. He said “ There is a tremendous potential to increase shareholders’ value. The Board and the management is fully committed to the plan and has a clear strategy of increasing market share, driving growth of domestic market through import substitution and increasing specialized films export”. “ As we grow, a wider number of shareholders will reap the benefits post IPO,” He further said.

    International Packaging Films Limited recorded net sales of PKR 19.9 billion in the year 2023 while its gross margin for the financial year 2023 remained 27%. Its profit before tax for year 2023 was 2.9 billion while its net profit after tax was 1.6 billion. The company’s 3-year revenue CGAR remained at 41%.

    The group collectively offers a complete portfolio of packaging solutions, producing BOPP, CPP, and BOPET films, making it the first-ever group in Pakistan to provide one-window flexible packaging solutions, located at two strategically important locations in the country.

    Also Read: How ABHI and Soorty Financially Empowered Labor in Pakistan